MFMagdalena Fąfara

Magdalena Fąfara

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article


Magdalena Fąfara has a total of 9 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • Open Access

    INFLUENCE OF THE GUT MICROBIOME ON THE PATHOGENESIS AND CLINICAL COURSE OF ATOPIC DERMATITIS

    by Amelia Sieradzka, Magdalena Fąfara, Margarita Jeczkało, Monika Kosiorowska, Agata Kowalczyk, Joanna Lasoń, Marcelina Makulska, Weronika Płachta, Wiktoria SęK, Cezary Wegenko

    Background: Atopic Dermatitis is a chronic inflammatory skin disease with a multifactorial pathogenesis involving genetic, immunological, and environmental factors. Recent research has highlighted the important role of the gut microbiome in modulating systemic immune responses and influencing the course of inflammatory diseases through the gut-skin axis. Aim: The aim of this study was to review current knowledge on the impact of the gut microbiome on the pathogenesis and clinical course of atopic dermatitis. Material and methods: A narrative literature review was conducted using databases such as PubMed, Scopus, and Web of Science. Articles from 2018-2026 were analyzed using keywords including „atopic dermatitis”, „gut microbiome”, „gut–skin axis”, „dysbiosis” and „probiotics”. The review included original studies, systematic reviews, and meta-analyses on the link between gut microbiota and atopic dermatitis. Results: Alterations in gut microbiota composition (dysbiosis), including reduced microbial diversity and decreased abundance of beneficial bacteria, were associated with the development and severity of atopic dermatitis. The gut microbiome influences disease progression through immune system modulation, production of short-chain fatty acids, and regulation of intestinal barrier integrity. Evidence also suggests that microbiome-targeted therapies, such as probiotics and dietary interventions, may have beneficial effects on disease outcomes. Conclusion: The gut microbiome significantly influences the development and course of atopic dermatitis. Understanding the gut-skin axis may help develop new therapies to restore microbial balance and improve outcomes.

  • Open Access

    ARTIFICIAL INTELLIGENCE CHATBOTS IN PATIENT EDUCATION: OPPORTUNITIES, RISKS, AND ETHICAL CHALLENGES

    by Wiktoria SęK, Agata Kowalczyk, Magdalena Fąfara, Margarita Jeczkało, Monika Kosiorowska, Joanna Lasoń, Marcelina Makulska, Weronika Płachta, Amelia Sieradzka, Cezary Wegenko

    Artificial intelligence chatbots and large language models are increasingly used to obtain, simplify, and personalize medical information for patients. This narrative medical review synthesizes 40 recent studies on chatbot-supported patient education across emergency medicine, cardiology, oncology, ophthalmology, gastroenterology, dermatology, orthopedics, otolaryngology, urology, pain medicine, nursing, and health-literacy research. The review evaluates opportunities, risks, and ethical challenges associated with patient-facing AI communication. The evidence suggests that chatbots can generate fluent explanations, improve access to plain-language materials, support appointment preparation, and reduce the workload of drafting educational content. However, important limitations recur across the literature, including excessive reading level, incomplete or unsafe advice, weak source transparency, fabricated references, model variability, language-related inequity, and patient overtrust in fluent but unverified answers. Ethically acceptable implementation should therefore treat chatbots as supervised communication-support tools rather than autonomous medical educators. Clinical use should require clinician-approved source material, explicit AI disclosure, readability testing, escalation instructions, model-version documentation, multilingual validation, and post-deployment monitoring. Under such safeguards, AI chatbots may strengthen patient education, but unsupervised deployment may intensify existing problems in online medical information.

  • Open Access

    COMPREHENSIVE TREATMENT OF TYPE 2 DIABETES IN PATIENTS WITH OBESITY: THE ROLE OF PATIENT EDUCATION, WEIGHT REDUCTION, PHARMACOTHERAPY AND LIFESTYLE MODIFICATION - A NARRATIVE REVIEW

    by Magdalena Fąfara, Margarita Jeczkało, Monika Kosiorowska, Agata Kowalczyk, Joanna Lasoń, Marcelina Makulska, Weronika Płachta, Wiktoria SęK, Amelia Sieradzka, Cezary Wegenko

    Type 2 diabetes and obesity are closely connected chronic conditions that require a comprehensive, patient-centred approach. Traditional management focused primarily on glycaemic control, whereas contemporary care increasingly recognizes weight reduction, cardiovascular-kidney-metabolic risk reduction and digital health tools as integral components of treatment. This narrative review synthesizes current evidence on the complex management of type 2 diabetes in adults with obesity, with emphasis on diabetes self-management education and support, intentional weight loss, lifestyle modification, pharmacotherapy and technology-enabled care. Publications were selected from PubMed-indexed literature, clinical guidelines, systematic reviews, meta-analyses and randomized controlled trials relevant to the intersection of diabetes, obesity, education, lifestyle and innovative health technologies. Education can improve glycaemic control and adherence. Structured weight-management interventions can support clinically meaningful weight loss and, in selected patients, remission of type 2 diabetes. Nutrition therapy and physical activity remain foundational, but their implementation requires individualized counselling, behavioural strategies and attention to social determinants of health. Pharmacotherapies such as metformin, sodium-glucose cotransporter 2 inhibitors (SGLT2 inhibitors), glucagon-like peptide-1 receptor agonists (GLP-1 receptor agonists) and dual glucose-dependent insulinotropic polypeptide/glucagon-like peptide-1 receptor agonists (dual GIP/GLP-1 receptor agonists) have shifted treatment from a purely glucose-centred model toward weight-centred. Digital health applications, wearable devices and continuous glucose monitoring may strengthen education and self-management, although equity and long-term engagement remain. Integrated care models combining education, weight management, pharmacotherapy and digital follow-up are likely to produce the greatest clinical and public health benefit.

  • Open Access

    GUT MICROBIOTA IN OBESITY AND METABOLIC SYNDROME: PATHOPHYSIOLOGY, CURRENT INSIGHTS AND THERAPEUTIC PERSPECTIVES

    by Agata Kowalczyk, Magdalena Fąfara, Margartia Jeczkało, Monika Kosiorowska, Joanna Lasoń, Marcelina Makulska, Weronika Płachta, Wiktoria SęK, Amelia Sieradzka, Cezary Wegenko

    The gut microbiota is increasingly recognized as a significant factor influencing the development of obesity and metabolic syndrome, not only through its role in digestion and nutrient metabolism, but also through its regulation of inflammation, intestinal barrier integrity, glucose and lipid metabolism, and hormonal signaling. The aim of this study was to present the current knowledge regarding the role of the gut microbiota in the pathophysiology of metabolic disorders, with particular emphasis on clinical data and the potential for therapeutic intervention on the microbiome. This study is a narrative review based on a systematic analysis of the literature. The full texts of 77 scientific publications from 2016–2026 were analyzed, of which 48 were included in the final synthesis. Studies on obesity, metabolic syndrome, dietary interventions, probiotics, prebiotics, synbiotics, fecal microbiota transplantation, and next-generation therapies were included. Available data indicate that dietary interventions, weight loss, increased fiber intake, and dietary strategies supporting microbiota diversity currently have the greatest practical significance. Probiotics, synbiotics, Akkermansia muciniphila, and fecal microbiota transplantation remain promising therapeutic approaches, but they still require further validation. The gut microbiota may in the future become a component of personalized treatment for metabolic disorders; however, its clinical application requires further research, standardization of methods, and identification of patient populations that may benefit the most.